Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease Patients
| Autor: | Cheng Zhang, Jens Nielsen, Adil Mardinoglu, Muhammad Arif, Ozlem Altay, Xiangyu Li, Burcin Saglam, Dilek Ural, Woong-Hee Kim, Mujdat Zeybel, Saeed Shoaie, Mathias Uhlén, Hong Yang, Murat Akyildiz, Jochen M. Schwenk, Mehmet Gokhan Gonenli, Claudia Fredolini, Jan Borén |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Creatinine business.industry Inflammation Mitochondrion medicine.disease medicine.disease_cause humanities chemistry.chemical_compound Endocrinology chemistry Weight loss Internal medicine Nonalcoholic fatty liver disease medicine Uric acid medicine.symptom Steatosis business Oxidative stress |
| DOI: | 10.1101/2021.05.20.21257480 |
| Popis: | Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMA) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondria and eventually removes excess fat from the liver. Here, we tested the safety and efficacy of CMA in NAFLD patients in a placebo-controlled 10-week study. We found that CMA significantly decreased hepatic steatosis and levels of aspartate aminotransferase, alanine aminotransferase, uric acid, and creatinine, whereas found no differences on these variables in the placebo group after adjustment for weight loss. By integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomics data, we revealed the underlying molecular mechanisms associated with the reduced hepatic fat and inflammation in NAFLD patients and identified the key players involved in the host-microbiome interactions. In conclusion, we observed that CMA can be used develop a pharmacological treatment strategy in NAFLD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|